BTLA
Overview
BTLA (B and T lymphocyte attenuator, also CD272) is an inhibitory co-receptor expressed on lymphocytes and dendritic cells. It interacts with HVEM (TNFRSF14) to suppress T cell activation. BTLA is implicated in T-cell exhaustion in the tumor microenvironment and is under investigation as an immunotherapy target.
Alterations observed in the corpus
- Implicated in T-cell exhaustion in NPC; tifcemalimab (JS004), an anti-BTLA antibody, is under clinical investigation PMID:24952746
- BTLA specifically upregulated in Cluster 3 of cholangiocarcinoma alongside PDCD1 (PD-1) and PDCD1LG2 (PD-L2), motivating immune-checkpoint blockade as a candidate therapeutic strategy in that subtype PMID:28667006
Cancer types (linked)
- NPC: BTLA contributes to immune exhaustion; tifcemalimab in clinical development PMID:24952746
Co-occurrence and mutual exclusivity
No data in current corpus.
Therapeutic relevance
- Tifcemalimab (JS004) — anti-BTLA antibody; clinical investigation in NPC PMID:24952746
Open questions
No conflicts in current corpus.
Sources
This page was processed by entity-page-writer on 2026-05-11. - PMID:28667006
This page was processed by wiki-cli on 2026-05-15.